Clinical Trial Finder

Inclusion Criteria:

1. Ability to understand and the willingness to sign a written informed consent document. 2. Age≥ 18 and≤ 75 years. 3. Clinical/ Histological/ cytological/ Imaging examination proven Oral/Oropharynx Squamous-cell carcinoma (Tongue, buccal mucosa, mouth floor, hard palate, Molar area), the depth of invasion > 4mm in preoperative assessment. 4. In line with clinical stage I / II stage (T1-2 N0 M0; AJCC 2010) and receiving surgical resection. 5. KPS≥ 70. 6. Normal bone marrow reserve function and normal liver, kidney function. 7. Expected survival period≥ 6 months.

Exclusion Criteria:

1. Inability to provide an informed consent. 2. Evidence of oral distant metastasis or other malignancies. 3. The patient has received prior surgery for primary tumor or lymph node ( except for biopsy ) 4. Prior radiotherapy for primary tumor. 5. The patient has previously received anti-tumor biological targeted therapy. 6. The patient has received chemotherapy or immunotherapy for primary tumors. 7. Prior malignancy within the previous 5 years (except for cured skin basal cell carcinoma or cervical carcinoma in situ) 8. With 3-4 grad Allergy to any drug in the treatment. 9. Peripheral neuropathy> 1 grade. 10. Any unstable systematic disease (including active infection, uncontrolled high blood pressure, unstable angina, onset of angina within the last 3 months, congestive heart failure, myocardial infarction within the previous 12 months, severe arrhythmia needing drug treatment, liver, kidney or metabolic disease) 11. HIV positive. 12. Chronic diseases requiring immune agents or hormone therapy. 13. Pregnant or lactating women. 14. Drug/alcohol abuse, psychological or spiritual illness that may interfere compliance to the study. 15. Patients with epilepsy requiring medications (such as steroids or antiepileptic drugs) 16. The patient has participated in other experimental therapy studies within 30 days. 17. Researchers believe that the situation is unsuitable for participation in the group

Objective: To evaluate the effect of radiotherapy on the neck of early oral cancer with poor pathologic factors. This is a randomized, prospective, open, multicenter study. Intervention: Patients receive primary tumor resection followed by radiotherapy. Control: Patients receive primary tumor resection with selective neck dissection. Primary: 2 years neck control rates. Secondary: Disease-free survival (1, 2, 3, 5 years) Overall survival (3, 5 years) Quality of life. Endpoint definition: 1 year, 2 years, 3 years, 5 years disease-free survival is defined as: patients proportion from the date of surgery completion to 1 year, 2 years, 3 years, 5 years did not find clear evidence of recurrence or metastasis. 3 years, 5 years overall survival is defined as: the proportion of patients who survived from the beginning of the study to the third and fifth year in the total enrollment.

Arms

Experimental: Radiotherapy

Primary surgery & Radiotherapy

Active Comparator: Elective neck dissection

Primary surgery & Elective neck dissection

Interventions

Radiation: - Radiotherapy

Radiotherapy after primary surgery in the treatment of early oral cancer based on adverse pathological factor

Procedure: - Elective neck dissection

Elective neck dissection after primary surgery in the treatment of early oral cancer based on adverse pathological factor